GlassScriptPhysician profile
Elhami Hannan
NPI 1093803884
$8,512.10
in general payments reported to CMS, 2019-2025
17 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $125 · 2021: $116 · 2022: $293 · 2023: $5,922 · 2024: $941 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,002 · Consulting Fee: $2,700 · Travel and Lodging: $1,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,002.32 |
| Consulting Fee | $2,700.00 |
| Travel and Lodging | $1,682.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $6,110.84 | 2019-2025 | Filspari |
| Akebia Therapeutics INC | $826.67 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.45 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $232.01 | 2023-2024 | |
| Vifor Pharma, INC. | $155.73 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $149.93 | 2025 | Jynarque |
| Baxter Healthcare | $140.45 | 2023 | Renal - Pd |
| Novo Nordisk INC | $138.39 | 2024-2025 | Ozempic |
| Ardelyx, INC. | $126.30 | 2024 | Xphozah 30 Mg |
| Astrazeneca Pharmaceuticals LP | $125.79 | 2023 | Farxiga |
| Alexion Pharmaceuticals, INC. | $70.29 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $45.99 | 2024 | |
| Innovation Technologies INC | $33.98 | 2022 | |
| Novartis Pharmaceuticals Corporation | $32.89 | 2024-2025 | |
| Veloxis Pharmaceuticals, INC. | $21.68 | 2025 | Envarsus |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $19.20 | 2021 | |
| Alnylam Pharmaceuticals INC. | $13.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elhami Hannan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.